AnaptysBio

Youtube Subscribe

Open: 19.74 Close: 19.74 Change: 0.0

Don't invest in AnaptysBio before reading this automated analysis produce by an AI.

The game is changing. There is a new strategy to evaluate AnaptysBio fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AnaptysBio are: Inc, Pharmaceuticals, lead, company, work, Acne, Vulgaris, and the …

Concept Map

Semantic Network

Stock Summary

AnaptysBio, Inc. focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the.

Today's Summary

The leading companies working in the Acne Vulgaris market include Novan Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio Inc., Botanix Pharmaceuticals and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals. anaptysbio, inc. receives mixed analyst ratings and sets target price at $33.67.

Today's News

The leading companies working in the Acne Vulgaris market include Novan Inc., Bausch Health Americas, Inc., AOBiome LLC, Ascletis Pharmaceuticals, AnaptysBio Inc., Botanix Pharmaceuticals and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, Xenon Pharmaceuticals Inc., Origimm Biotechnology, Boston Pharmaceuticals. anaptysbio, inc. receives mixed analyst ratings and sets target price at $33.67.

Stock Profile

"AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California."

Keywords

This document will help you to evaluate AnaptysBio without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AnaptysBio are: Inc, Pharmaceuticals, lead, company, work, Acne, Vulgaris, and the most common words in the summary are: anaptysbio, inc, company, stock, insight, market, report, . One of the sentences in the summary was: receives mixed analyst ratings and sets target price at $33.67.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #anaptysbio #inc #company #stock #insight #market #report.

Read more →

Youtube Subscribe

---